Politics and Policy

About half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.

Sadly, President Trump has issued an executive order to expand these plans under the guise of consumer choice and lower costs.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.

CMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know

How did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.

Trump’s new proposal would broaden access to association health plans. Here’s six things to know.

Managed Healthcare Executive board members identify top challenges. How does your list compare?

This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.

The winds of change swept through healthcare in 2017. Here’s what 2018 could bring.

Shocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch

With the right preventions in place, hospitals and healthcare executives will be well positioned to respond to these four risks in 2018.

Overprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.

As 2017 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.

Insiders unmask what policy actions will continue and what will develop in the next year.

A new study reveals an important spillover effect of parental Medicaid coverage.

If signed into law, Trump’s tax reform will have substantive impacts on healthcare organizations and on individuals.

A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.

Experts weigh in on the findings from Managed Healtcare Executive’s 2017 State of the Industry Survey.

Experts share more about Alex Azar’s background and predict what his top agenda items are likely to be.

The key changes the Trump Administration has made that could make it more difficult for consumers to sign up for healthcare coverage.

There are tried and true methods to manage through turbulent times, both at the business and personal level. We can apply these methods as healthcare leaders.

While these types of programs have been in place for several years, it can be difficult to gauge who is using them and how, and whether they are achieving their intended goal.

Here are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.

PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.